SCHEMBL21712591

SCHEMBL21712591

CC(C)C(NC(=O)O)c1nc2cc(-c3ccnc(Cl)c3)sc2c(=O)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 7/20 0.46
▸ DBF4 Q9UBU7 7/20 0.46
▸ RAB9A P51151 4/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ KMT2A Q03164 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ ROCK1 Q13464 5/20 0.37
▸ CCNE1 P24864 3/20 0.37
▸ CDK2 P24941 3/20 0.37
▸ CDK5 Q00535 1/20 0.35
▸ CDK5R1 Q15078 1/20 0.35
▸ IDO1 P14902 1/20 0.34
▸ SMARCA2 P51531 1/20 0.34
▸ SMARCA4 P51532 1/20 0.34
▸ SPR P35270 1/20 0.34
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21712628 0.90 CDC7 (0.47) CDC7DBF4RAB9ASMN1; SMN2KDM4E
SCHEMBL21729493 0.89 AAK1 (0.42) CDC7DBF4RAB9ASMN1; SMN2KDM4E
SCHEMBL28457041 0.89 AAK1 (0.42) CDC7DBF4RAB9ASMN1; SMN2KDM4E
SCHEMBL21712637 0.86 CDC7 (0.47) CDC7DBF4RAB9ASMN1; SMN2KDM4E
SCHEMBL21712647 0.83 CDC7 (0.47) CDC7DBF4RAB9ASMN1; SMN2KDM4E
SCHEMBL21712646 0.83 CDC7 (0.47) CDC7DBF4RAB9ASMN1; SMN2KDM4E
SCHEMBL20572270 0.82 CDC7 (0.42) CDC7DBF4RAB9ASMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL21712612 0.82 CDC7 (0.46) CDC7DBF4RAB9ASMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL21712609 0.82 CDC7 (0.46) CDC7DBF4RAB9ASMN1; SMN2KDM4E
SCHEMBL21729495 0.81 CDC7 (0.43) CDC7DBF4RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10745410-B2 Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents ZENJI RESEARCH LABORATORIES (CN) 2020-08-18 — — US disclosed
US-20200055867-A1 SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS ZENJI RESEARCH LABORATORIES (CN) 2020-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055867-A1 SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS CDC7, CDK7, CDK17 CDC7 1/4885DBF4 1421/4885RAB9A 2362/4885
US-10745410-B2 Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents CDC7, CDK7, CDK17 CDC7 1/4885DBF4 1421/4885RAB9A 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback